FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509315795> ?p ?o ?g. }

• W2509315795 endingPage "1908" @default.
• W2509315795 startingPage "1902" @default.
• W2509315795 abstract "Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context of a MYB gene rearrangement. This phase II trial of the tyrosine kinase inhibitor (TKI) axitinib (Pfizer) tested the hypothesis that targeting pathways activated by MYB can be therapeutically effective for ACC.This is a minimax two-stage, phase II trial that enrolled patients with incurable ACC of any primary site. Progressive or symptomatic disease was required. Patients were treated with axitinib 5 mg oral twice daily; dose escalation was allowed. The primary end point was best overall response (BOR). An exploratory analysis correlating biomarkers to drug benefit was conducted, including next-generation sequencing (NGS) in 11 patients.Thirty-three patients were registered and evaluable for response. Fifteen patients had the axitinib dose increased. Tumor shrinkage was achieved in 22 (66.7%); 3 (9.1%) had confirmed partial responses. Twenty-five (75.8%) patients had stable disease, 10 of whom had disease stability for >6 months. The median progression-free survival (PFS) was 5.7 months (range 0.92-21.8 months). Grade 3 axitinib-related toxicities included hypertension, oral pain and fatigue. A trend toward superior PFS was noted with the MYB/NFIB rearrangement, although this was not statistically significant. NGS revealed three tumors with 4q12 amplification, producing increased copies of axitinib-targeted genes PDGFR/KDR/KIT. Two 4q12 amplified patients achieved stable disease for >6 months, including one with significant tumor reduction and the longest PFS on study (21.8 months).Although the primary end point was not met, axitinib exhibited clinical activity with tumor shrinkage achieved in the majority of patients with progressive disease before trial enrollment. Analysis of MYB biomarkers and genomic profiling suggests the hypothesis that 4q12 amplified ACCs are a disease subset that benefit from TKI therapy." @default.
• W2509315795 created "2016-09-16" @default.
• W2509315795 creator A5001959941 @default.
• W2509315795 creator A5002723616 @default.
• W2509315795 creator A5005230766 @default.
• W2509315795 creator A5005775817 @default.
• W2509315795 creator A5019970204 @default.
• W2509315795 creator A5023532213 @default.
• W2509315795 creator A5024957945 @default.
• W2509315795 creator A5036572642 @default.
• W2509315795 creator A5036927531 @default.
• W2509315795 creator A5052154004 @default.
• W2509315795 creator A5059814272 @default.
• W2509315795 creator A5061365371 @default.
• W2509315795 creator A5071357841 @default.
• W2509315795 creator A5072271778 @default.
• W2509315795 creator A5084443648 @default.
• W2509315795 date "2016-10-01" @default.
• W2509315795 modified "2023-10-17" @default.
• W2509315795 title "A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma" @default.
• W2509315795 cites W1495629113 @default.
• W2509315795 cites W1566570196 @default.
• W2509315795 cites W1589801626 @default.
• W2509315795 cites W1838206777 @default.
• W2509315795 cites W1974202442 @default.
• W2509315795 cites W1975532682 @default.
• W2509315795 cites W1992894543 @default.
• W2509315795 cites W2003477566 @default.
• W2509315795 cites W2007625022 @default.
• W2509315795 cites W2027658726 @default.
• W2509315795 cites W2056203481 @default.
• W2509315795 cites W2077813502 @default.
• W2509315795 cites W2096514095 @default.
• W2509315795 cites W2099835784 @default.
• W2509315795 cites W2127917633 @default.
• W2509315795 cites W2139085647 @default.
• W2509315795 cites W2185318137 @default.
• W2509315795 cites W2190282709 @default.
• W2509315795 cites W2195049161 @default.
• W2509315795 cites W223909586 @default.
• W2509315795 cites W2268032794 @default.
• W2509315795 cites W2914450711 @default.
• W2509315795 doi "https://doi.org/10.1093/annonc/mdw287" @default.
• W2509315795 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5035791" @default.
• W2509315795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27566443" @default.
• W2509315795 hasPublicationYear "2016" @default.
• W2509315795 type Work @default.
• W2509315795 sameAs 2509315795 @default.
• W2509315795 citedByCount "70" @default.
• W2509315795 countsByYear W25093157952017 @default.
• W2509315795 countsByYear W25093157952018 @default.
• W2509315795 countsByYear W25093157952019 @default.
• W2509315795 countsByYear W25093157952020 @default.
• W2509315795 countsByYear W25093157952021 @default.
• W2509315795 countsByYear W25093157952022 @default.
• W2509315795 countsByYear W25093157952023 @default.
• W2509315795 crossrefType "journal-article" @default.
• W2509315795 hasAuthorship W2509315795A5001959941 @default.
• W2509315795 hasAuthorship W2509315795A5002723616 @default.
• W2509315795 hasAuthorship W2509315795A5005230766 @default.
• W2509315795 hasAuthorship W2509315795A5005775817 @default.
• W2509315795 hasAuthorship W2509315795A5019970204 @default.
• W2509315795 hasAuthorship W2509315795A5023532213 @default.
• W2509315795 hasAuthorship W2509315795A5024957945 @default.
• W2509315795 hasAuthorship W2509315795A5036572642 @default.
• W2509315795 hasAuthorship W2509315795A5036927531 @default.
• W2509315795 hasAuthorship W2509315795A5052154004 @default.
• W2509315795 hasAuthorship W2509315795A5059814272 @default.
• W2509315795 hasAuthorship W2509315795A5061365371 @default.
• W2509315795 hasAuthorship W2509315795A5071357841 @default.
• W2509315795 hasAuthorship W2509315795A5072271778 @default.
• W2509315795 hasAuthorship W2509315795A5084443648 @default.
• W2509315795 hasBestOaLocation W25093157951 @default.
• W2509315795 hasConcept C121608353 @default.
• W2509315795 hasConcept C126322002 @default.
• W2509315795 hasConcept C143998085 @default.
• W2509315795 hasConcept C151730666 @default.
• W2509315795 hasConcept C203092338 @default.
• W2509315795 hasConcept C2776539811 @default.
• W2509315795 hasConcept C2777546739 @default.
• W2509315795 hasConcept C2778822529 @default.
• W2509315795 hasConcept C2779134260 @default.
• W2509315795 hasConcept C2779231225 @default.
• W2509315795 hasConcept C2779343474 @default.
• W2509315795 hasConcept C2779490328 @default.
• W2509315795 hasConcept C535046627 @default.
• W2509315795 hasConcept C71924100 @default.
• W2509315795 hasConcept C86803240 @default.
• W2509315795 hasConcept C90924648 @default.
• W2509315795 hasConceptScore W2509315795C121608353 @default.
• W2509315795 hasConceptScore W2509315795C126322002 @default.
• W2509315795 hasConceptScore W2509315795C143998085 @default.
• W2509315795 hasConceptScore W2509315795C151730666 @default.
• W2509315795 hasConceptScore W2509315795C203092338 @default.
• W2509315795 hasConceptScore W2509315795C2776539811 @default.
• W2509315795 hasConceptScore W2509315795C2777546739 @default.
• W2509315795 hasConceptScore W2509315795C2778822529 @default.
• W2509315795 hasConceptScore W2509315795C2779134260 @default.

• next